Tirzepatide (brand names Mounjaro for type 2 diabetes, Zepbound for obesity) and semaglutide (Ozempic for T2D, Wegovy for obesity) are both once-weekly injectable drugs that reduce appetite and food intake by acting on receptors in the gut and brain. Their core difference: semaglutide is a selective GLP-1 receptor agonist — it mimics the incretin hormone GLP-1. Tirzepatide is a dual GIP/GLP-1 receptor agonist — it simultaneously mimics both GIP and GLP-1. Both hormones are naturally secreted by the gut after eating and regulate insulin secretion, appetite, and gastric emptying. The addition of GIP receptor agonism in tirzepatide accounts for its meaningfully greater weight loss efficacy.
The head-to-head question was definitively addressed by SURMOUNT-5 (published 2025): in adults with obesity but without diabetes, tirzepatide 10mg or 15mg produced approximately 20% weight loss vs approximately 14% for semaglutide 2.4mg — a statistically significant 6-percentage-point gap. This is a clinically meaningful difference at the individual level: for a 220lb person, tirzepatide would be expected to produce an additional 13 lbs of weight loss compared to semaglutide.
| Category | Tirzepatide (Mounjaro/Zepbound) | Semaglutide (Ozempic/Wegovy) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist — novel mechanism; GIP agonism amplifies GLP-1 effects and reduces GLP-1-associated nausea | GLP-1 agonist only — the first GLP-1 agonist to show dramatic obesity weight loss; mechanism well-characterized and extensively studied |
| Maximum weight loss (phase 3 trials) | 20.9% (SURMOUNT-1, 15mg, 72 weeks) | 14.9% (SELECT, 2.4mg, 68 weeks) |
| Cardiovascular outcome trial | SURPASS-CVOT (ongoing at time of writing) — no large CV outcome RCT published yet; SURMOUNT-1 and SURPASS trials show reduced HbA1c, BP, triglycerides, and waist circumference (all CV risk factors) | SELECT trial (2023, N=17,604, 3.3yr): 20% reduction in MACE, 28% reduction in CV mortality — FDA approved semaglutide for CV risk reduction in 2024 in non-diabetic obese adults with CVD; this is semaglutide's most important advantage currently |
| Nausea (highest dose) | ~33–35% (tirzepatide 15mg) | ~44% (semaglutide 2.4mg) — likely due to pure GLP-1 action without GIP buffering |
| Constipation | ~34% — higher than semaglutide; thought to relate to greater gastric slowing from dual agonism | ~24% |
| T2D glycemic control | Superior HbA1c reduction — SURPASS-2 (N=1,879): tirzepatide 15mg reduced HbA1c –2.59% vs semaglutide 1mg –1.86%; tirzepatide achieved normal HbA1c in a majority of patients | Excellent glycemic control — the first-choice GLP-1 for many T2D guidelines, with HbA1c reductions of 1.4–1.8%; semaglutide 2mg (Rybelsus oral) is the only oral GLP-1 agonist |
| Dose schedule | Once weekly injection; 2.5mg start, escalate by 2.5mg every 4 weeks to target dose (maximum 15mg) | Once weekly injection; 0.25mg start, escalate over 16–20 weeks to 2.4mg (Wegovy) or 2mg (Ozempic) |
| Approved indications (US, 2026) | Mounjaro: T2D (2022) · Zepbound: obesity/overweight with comorbidities (2023) · sleep apnea reduction (2025) | Ozempic: T2D (2017) · Wegovy: obesity (2021) · CV risk reduction in obese non-diabetics with CVD (2024) |
| List price (monthly) | ~$1,070/month (Zepbound); patient assistance programs and manufacturer savings cards widely available; compounded tirzepatide was available but FDA is phasing out compound-pharmacy versions | ~$1,350/month (Wegovy); manufacturer savings card reduces cost for commercially insured; compounded semaglutide widely available but FDA declared shortage resolved 2025 |
| Insurance coverage | Variable; T2D indication (Mounjaro) broadly covered; obesity indication coverage improving but still inconsistent | Variable; same pattern — T2D (Ozempic) broadly covered; Wegovy obesity coverage variable; some states cover via Medicaid |
For years, GIP (glucose-dependent insulinotropic polypeptide) was considered a "diabetogenic" hormone — studies showed that GIP receptor agonism could promote fat storage, and GIPR knockout mice were resistant to diet-induced obesity. This was one reason early GLP-1 drug development focused on GLP-1 exclusively. Eli Lilly's discovery that combining GIP agonism with GLP-1 agonism produces more weight loss than GLP-1 alone required a mechanistic rethink: it appears that in the context of concurrent GLP-1 receptor activation, GIP receptor activation in the hypothalamus (specifically the arcuate nucleus) potentiates appetite suppression synergistically. Separately, GIP agonism in the area postrema may reduce the nausea that limits maximum tolerated GLP-1 doses — meaning tirzepatide can effectively "deliver" more GLP-1-like activity at each dose without proportionally more nausea. The net result: greater weight loss with slightly better GI tolerability than the naive prediction from GLP-1 dose-escalation alone.